Bruker Corporation
BRKR
Rang in aandelen
#2314
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Aandeelprijs
$56.53
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$8.61B
Verandering (1 dag)
2.09%
Verandering (1 jaar)
45.77%
Land
US
Handel Bruker Corporation (BRKR)
Categorie
Healthcare
Omzet van Bruker Corporation (BRKR)
Omzet in Jun 2026 TTM: $3.50B
Volgens de laatste financiële rapporten van Bruker Corporation bedraagt de huidige omzet van het bedrijf (TTM) $3.50B. In 2024 behaalde het bedrijf een omzet van $3.37B een stijging ten opzichte van de omzet in het jaar 2023, die $2.96B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Bruker Corporation van 2000 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $3.50B | 1.84% |
| 2025 | $3.44B | 2.08% |
| 2024 | $3.37B | 13.56% |
| 2023 | $2.96B | 17.14% |
| 2022 | $2.53B | 4.67% |
| 2021 | $2.42B | 21.66% |
| 2020 | $1.99B | -4.11% |
| 2019 | $2.07B | 9.34% |
| 2018 | $1.90B | 7.34% |
| 2017 | $1.77B | 9.59% |
| 2016 | $1.61B | -0.77% |
| 2015 | $1.62B | -10.23% |
| 2014 | $1.81B | -1.66% |
| 2013 | $1.84B | 2.68% |
| 2012 | $1.79B | 8.46% |
| 2011 | $1.65B | 26.58% |
| 2010 | $1.30B | 17.08% |
| 2009 | $1.11B | 0.67% |
| 2008 | $1.11B | 102.18% |
| 2007 | $547.58M | 25.64% |
| 2006 | $435.83M | 46.46% |
| 2005 | $297.57M | 4.62% |
| 2004 | $284.42M | 9.11% |
| 2003 | $260.68M | 124.01% |
| 2002 | $116.37M | 25.54% |
| 2001 | $92.69M | 21.00% |
| 2000 | $76.60M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $46.59B | 1,231.15% |
US
|
|
| $35.48B | 913.94% |
IE
|
|
| $25.84B | 638.28% |
US
|
|
| $21.00B | 499.95% |
US
|
|
| - | - |
DE
|
